Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

@article{Attard2009AntitumorAW,
  title={Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.},
  author={Gerhardt Attard and Alison H. M. Reid and David R Olmos and Johann S de Bono},
  journal={Cancer research},
  year={2009},
  volume={69 12},
  pages={4937-40}
}
Abiraterone acetate is a potent, selective, and orally bioavailable small molecule inhibitor of CYP17, an enzyme that catalyzes two key serial reactions (17 alpha hydroxylase and 17,20 lyase) in androgen and estrogen biosynthesis. Clinical trials have confirmed that specific inhibition of CYP17 is safe and results in clinically important antitumor activity in up to 70% of castrate patients with advanced prostate cancer resistant to currently available endocrine therapies. These clinical data… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…